AbbVie-backed Carisma's 'CAR-M' tech shrinks tumors in mouse models of ovarian cancer

AbbVie-backed Carisma's 'CAR-M' tech shrinks tumors in mouse models of ovarian cancer

Source: 
Fierce Biotech
snippet: 

The researchers engineered CAR-Ms to express the tumor target HER2 and tested it in mouse models of human solid tumors. A single infusion of the therapy shrank tumors and prolonged survival in the animals, the team reported in Nature Biotechnology. The technology is now being developed by Carisma Therapeutics, a Penn spinout that raised $53 million in a series A financing led by AbbVie and HealthCap in 2018. (It then extended the funding round, picking up an additional $6 million.)